Compare Innodata Inc (INOD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Neurocrine Biosciences Inc — how do they compare? Innodata Inc trades at $61.24 (market cap $2.10B), while Neurocrine Biosciences Inc trades at $141.66 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.8× Innodata Inc's market cap, and Innodata Inc is more actively traded (989,493 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Neurocrine Biosciences Inc for 23 Days on average.
| INOD | NBIX | |
|---|---|---|
Market Cap | $2.10B | $14.36B |
Volume | 989,493 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $121.50 | $185.50 |
52-Week Low | $34.45 | $123.10 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $1.86B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innodata (INOD) trades at $60.80, down 4.12% today amid bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and robust profitability (37.74% ROE, 14.66% net margin). Recent quarterly results exceeded expectations, with Q1 2026 EPS of $0.42 beating estimates by 223%. The company is expanding into motion-capture AI and agentic reinforcement learning, positioning for growth in the AI infrastructure sector.
Despite premium valuations (P/E 47.43), INOD's strong execution and AI market positioning offer upside potential. Key risks include customer concentration and competitive pressures. Analyst consensus is bullish (66.7% buy ratings), though technical indicators suggest near-term caution with the stock trading below key resistance levels.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
